Nektar and Syndax Team Up

I think this is another example of the optionality Nektar has with it’s pipeline. I think it will be an exciting next month (and several years) as we start to see the results from some of these trials.

I’m also interested to see other partnerships that could potentially start popping up.

https://seekingalpha.com/news/3360510-syndax-nektar-therapeu…

Phase 1b/2 clinical trial assessing the combination of entinostat and NKTR-214.

Entinostat is an orally available small molecule designed to block the function of immune suppressive cells in the tumor microenvironment.

NKTR-214 is designed to stimulate the immune system to attack cancer cells by targeting CD122 receptors on the surface of immune cells called CD8+ effector T cells and Natural Killer cells.

  • Austin

Shopify (SHOP) Ticker Guide

For information on all of my current holdings view my profile here: http://my.fool.com/profile/CMFAleeb/info.aspx

2 Likes